Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Impact · against what's priced in

Parabilis (PBLS) is likely to see a positive price reaction due to updated Phase I/II data showing a 72.2% response rate, which meaningfully exceeds the 41% reported for the approved competitor nirogacestat. The alignment with the FDA on a Phase III trial starting in H1 2027, backed by a cash runway into 2030, provides a clear, funded path to registration.

PBLS+0.70: No priced-in read yet
In context: The 72.2% objective response rate is substantially higher than nirogacestat's 41%, and the lack of treatment-related discontinuations across 76 patients suggests a superior safety profile. Furthermore, cash runway extending to 2030 removes immediate financing risk for the 2027 Phase III trial start.

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

phase 3▲1500%
clinical trials▲212%
biotech▲54%
PBLS
desmoid tumors
drug development
fda

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

What matters in this story

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

What matters in this story

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

How each ticker is affected

Track these names every morning.

Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

What matters in this story

Next reads from the same story arc

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

What matters in this story

Next reads from the same story arc

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

How each ticker is affected

Track these names every morning.

Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial